Anonymous JEL referee. 2002. Mailed to Daniel Klein by John McMillian, May, 2002.
Arno, P. S., K. Bonuck, and M. Davis. 1995. Rare Diseases, Drug Development, and AIDS: The Impact of the Orphan Drug Act. Milbank Quarterly 73, no. 2: 23152.
Bakke, O. M., M. Manocchia, de F. Abajom, K. Kaitin, and L. Lasagna. 1995. Drug Safety Discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: A Regulatory Perspective. Clinical Pharmacology and Therapeutics 58, no. 1: 10817.
Becker, Gary. 2002. Get the FDA out of the Way, and Drug Prices will Drop. Business Week (Sept. 16, 2002).
. 2004. Big Ideas: Patients’ Rights. The Milken Institute Review. Second Quarter, p. 93–4.
Beisler, Joshua H. 2000. Dietary Supplements and Their Discontents: FDA Regulation and the Dietary Supplement Health and Education Act of 1994. Rutgers Law Journal 31: 51151.
Benham, Lee, and Alexandra Benham. 1975. Regulating through the Professions: A Perspective on Information Control. Journal of Law and Economics 18, no. 2: 42148.
Berndt, Ernst R. 2005. The United States’ Experience with Direct-to-Consumer Advertising of Prescription Drugs: What Have We Learned? Paper presented at the International Conference on Pharmaceutical Innovation, Taipei, Taiwan. In Frank A. Sloan and Chee-Ruey Hsieh, eds., Promoting and Coping with Pharmaceutical Innovation: An International Perspective. Cambridge University Press, late 2006.
Berndt, Ernst R., Adrian H. B. Gottschalk, Tomas Philipson and Matthew W. Strobeck. 2005a. Assessing the Impacts of the Prescription Drug User Fee Acts (PDUFA) on the FDA Approval Process. Forum for Health Economics & Policy, article 2.
. 2005b. Industry Funding of the FDA: Effects of PDUFA on Approval Times and Withdrawal Rates, Nature Reviews: Drug Discovery, 4(7), July 2005: 545–54.
Berndt, E.R., R. S. Pindyck, and P. Azoulay. 2000. Consumption Externalities and Diffusion in Pharmaceutical Markets: Anti-Ulcer Drugs. NBER Working Paper #7772.
Berndt, E.R. et al. 1997. The Roles of Marketing, Product Quality, and Price Competition in the Growth and Composition of the US Antiulcer Drug Industry. In T.F Bresnahan and R.J. Gordon, eds., The Economics of New Goods, 58, NBER Studies in Income and Wealth. Chicago: University of Chicago Press: 277–322.
Brown, Walter A. and B. Severs. 1999. Placebos: Fooling the Body to Heal Itself. USA Today (July): 3233.
Buchanan, James M. 2005. Afraid to Be Free: Dependency as Desideratum. Public Choice 34: 19–31.
Coscelli, Andrea. 2000. The Importance of Doctors’ and Patients’ Preferences in the Prescription Decision. Journal of Industrial Economics 48(3): 349–69.
Danzon, Patricia M., and Eric L. Keuffel. 2007. Regulation of the Pharmaceutical Industry. Paper prepared for the NBER Conference on Regulation, September 2005; paper revised September 12, 2007.
Demsetz, Harold. 1969. Information and Efficiency: Another Viewpoint. Journal of Law and Economics 12(1): 1–22.
DiMasi, Joseph A. 2000. New Drug Innovation and Pharmaceutical Industry Structure: Trends in the Output of Pharmaceutical Firms. Drug Information Journal 34: 1169–94.
. 2001. New Drug Development in the United States from 1963 to 1999. Clinical Pharmacology and Therapeutics 69(5): 286–96.
DiMasi, Joseph A., and Cherie Paquette. 2004. The Economics of Follow-on Drug Research and Development. Pharmacoeconomics 22(Suppl. 2): 1–14.
DiMasi, Joseph A., Jeffrey S. Brown, and Louis Lasagna. 1996. An Analysis of Regulatory Review Times of Supplemental Indications for Already-Approved Drugs: 19891994. Drug Information Journal 30: 315–337.
DiMasi, Joseph A., Ronald W. Hansen, and Henry G. Grabowski. 2003. The Price of Innovation: New Estimates of Drug Development Costs. Journal of Health Economics 22: 151–85.
. 2005a. Extraordinary Claims Require Extraordinary Evidence. Journal of Health Economics 24(5): 1034–44.
. 2005b. Setting the Record Straight on Setting the Record Straight: Response to the Light and Warburton Rejoinder. Journal of Health Economics 24(5): 1049–53.
Grabowski, H. G. 1980. Regulation and the International Diffusion of Pharmaceuticals. In The International Supply of Medicines, edited by R. B. Helms, 536. Washington, D.C.: American Enterprise Institute for Public Policy Research.
Grabowski, Henry G., and John M. Vernon. 1977. Consumer Protection Regulation in Ethical Drugs. American Economic Review 67(1): 359–64.
. 1996. Longer Patents for Increased Generic Competition in the U.S.: The Waxman-Hatch Act after One Decade. PhamacoEconomics 10, no. 2: 11023.
Grabowski, Henry G., John M. Vernon, and Lacy Glenn Thomas. 1978. Estimating the Effects of Regulation on Innovation: An International Comparative Analysis of the Pharmaceutical Industry. Journal of Law and Economics 21(1): 133–63.
. 1995b. How FDA Is Causing a Technological Exodus: A Comparative Analysis of Medical Device RegulationUnited States, Europe, Canada, and Japan. Washington, D.C.: Competitive Enterprise Institute, March.
Klein, Daniel B. and Charlotta Stern. 2006. Economists’ Policy Views and Voting. Public Choice 126: 331–42.
Klein, D.B. and A. Tabarrok. 2002. Is the FDA Safe and Effective? [a sophisticated Web site of 35,000 words reviewing economic analysis of the FDA] Online at www.FDAReview.org. A project of the Independent Institute.
. 2004. Who Certifies Off-Label? Regulation, Summer 2004: 60–3. Link
. 2008. Do Off-Label Drug Practices Argue against FDA Efficacy Requirements? A Critical Analysis of Physicians’ Argumentation for Initial Efficacy Requirements. American Journal of Economics and Sociology.
Leffler, Keith B. 1981. Persuasion or Information? The Economics of Prescription Drug Advertising. Journal of Law and Economics 24, 1: 4574.
Lewin, Peter. 2007. Facts, Values, and the Burden of Proof. The Independent Review 11(4): 503–17.
Libecap, Gary D. 1992. The Rise of the Chicago Packers, and the Origins of Meat Inspection and Antitrust. NBER Historical Working Paper No. 29. Economic Inquiry (April 1992): 24262.
Lichtenberg, F. R. 1996. Do (More and Better) Drugs Keep People Out of Hospitals? American Economic Review 86 (2): 384–88.
. 2001a. The Benefits and Costs of Newer Drugs: Evidence from the 1996 Medical Expenditure Panel Survey. NBER Working Paper Series 8147.
. 2001b. The Effect of New Drugs On Mortality from Rare Diseases and HIV. NBER Working Paper Series 8677.
Light, Donald W., and Rebecca N. Warburton. 2005a. Extraordinary Claims Require Extraordinary Evidence. Journal of Health Economics 24(5): 1030–3.
. 2005b. Setting the Record Straight in the Reply by DiMasi, Hansen and Grabowski. Journal of Health Economics 24(5): 1045–8.
Ling, Davina C., Ernst R. Berndt, and Margaret K. Kyle. 2002. Deregulating Direct-to-Consumer Marketing of Prescription Drugs: Effects on Prescription and Over-the-Counter Product Sales. Journal of Law and Economics 45, Oct: 691–721.
Masson, Alison, and Paul H. Rubin. 1985. Matching Prescription Drugs and Consumers. New England Journal of Medicine 313 (August 22): 5135.
. 1986. Plugs for Drugs. Regulation (Sept./Oct.): 37–44.
McCloskey, Deirdre N., and Stephen T. Ziliak, 1996. The Standard Error of Regressions. Journal of Economic Literature 34: 97–114.
McMillan, John. 2002. Correspondence to Daniel Klein, May 21.
Meyers, A. S. 1991. The U.S. Orphan Drug Act: Should the Law Cover Highly Profitable Drugs? World Pharmaceutical Standards Review 1: 245.
. Ignorance Is Death: The FDA’s Advertising Restrictions. In American Health Care: Government, Market Processes, and the Public Interest, ed. Roger D. Feldman: 285–311. New Brunswick, NJ: Transaction Publishers.
. 1992. Realized Benefits from Switching Drugs. Journal of Law and Economics 35: 35169.
Thomas, L. G. 1990. Regulation and Firm Size: FDA Impacts on Innovation. Rand Journal of Economics 21, no. 4: 497517.
. 1996. Industrial Policy and International Competitiveness in the Pharmaceutical Industry. In Competitive Strategies in the Pharmaceutical Industry, ed. Robert B. Helms. Washington: American Enterprise Institute for Public Policy Research 107–29.
Tollison, Robert. 1996. Institutional Alternatives for the Regulation of Drugs and Medical Devices. In Advancing Medical Innovation: Health, Safety, and the Role of Government in the 21st Century, edited by Ralph Epstein, 17–40. Washington, D.C.: Progress and Freedom Foundation.
Viscusi, W. Kip. 1996. "Regulatory Reform and Liability for Pharmaceuticals and Medical Devices," Advancing Medical Innovation: Health, Safety and the Role of Government in the 21st Century. The Progress and Freedom Foundation, February 7, 1996: 79–102.
Viscusi, W. Kip, Joseph E. Harrington, Jr., and John M. Vernon. 2005. Economics of Regulation and Antitrust 4th edition. Cambridge: MIT Press.
Ward, Michael R. 2002. Drug Approval Overregulation. Regulation, Fall: 47–53.
Wardell, W. M. 1973. Introduction of New Therapeutic Drugs in the United States and Great Britain: An International Comparison. Clinical Pharmacology and Therapeutics 14, no. 5: 77390.
. 1978a. A Close Inspection of the Calm Look. Journal of the American Medical Association 239, no. 19: 200411.
. 1978b. The Drug Lag Revisited: Comparisons by Therapeutic Area of Patterns of Drugs Marketed in the U.S. and Great Britain from 1972 through 1976. Clinical Pharmacology and Therapeutics 24: 499524.